Floatz logo

Devimistat

Mucinous Adenocarcinoma of the Rectum

Wake Forest University Health SciencesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Mucinous Adenocarcinoma of the Rectum cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
University of Southern California
Phase 3BBB
Irinotecan
Fox Chase Cancer Center
Phase 3BBB
Eloxatin
Virginia Commonwealth University
Phase 3BBB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
PANITUMUMAB
John Hays
Phase 2B

View all 20 →

Same molecule, other indications

Devimistat is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →